WO2005112999A3 - Cancer treatment with inhibitors of collagen synthesis - Google Patents
Cancer treatment with inhibitors of collagen synthesis Download PDFInfo
- Publication number
- WO2005112999A3 WO2005112999A3 PCT/US2005/017732 US2005017732W WO2005112999A3 WO 2005112999 A3 WO2005112999 A3 WO 2005112999A3 US 2005017732 W US2005017732 W US 2005017732W WO 2005112999 A3 WO2005112999 A3 WO 2005112999A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- agents
- inhibitors
- cancer treatment
- collagen synthesis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 102000008186 Collagen Human genes 0.000 title 1
- 108010035532 Collagen Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229920001436 collagen Polymers 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 230000003367 anti-collagen effect Effects 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions and methods are provided for the treatment of tumors with a combination of anti-collagen agents and anti-neoplastic agents. In some embodiments one or more of the anti-collagen agents and anti-neoplastic agents may be provided in a biocompatible polymer matrix. The invention also provides prodrugs comprising anti-collagen and anti-tumor agent conjugates. The inventive compositions and methods can be useful in shrinking or reducing tumor size by abrogating drug diffusion barriers that are often the result of collagenous extracellular matrix of solid tumors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57261104P | 2004-05-20 | 2004-05-20 | |
| US60/572,611 | 2004-05-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005112999A2 WO2005112999A2 (en) | 2005-12-01 |
| WO2005112999A3 true WO2005112999A3 (en) | 2009-05-07 |
Family
ID=35428859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/017732 WO2005112999A2 (en) | 2004-05-20 | 2005-05-20 | Cancer treatment with inhibitors of collagen synthesis |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005112999A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101652150B (en) | 2006-12-01 | 2013-12-11 | 韦克福里斯特大学健康科学院 | Medical devices incorporating collagen inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485088A (en) * | 1982-03-26 | 1984-11-27 | Bio-Products, Inc. | Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs |
| US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
| US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
-
2005
- 2005-05-20 WO PCT/US2005/017732 patent/WO2005112999A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485088A (en) * | 1982-03-26 | 1984-11-27 | Bio-Products, Inc. | Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs |
| US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
| US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005112999A2 (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| WO2004087075A3 (en) | Compositions and methods for treating cancer | |
| LUC00011I2 (en) | ||
| WO2007047291A3 (en) | Anti-glypican-3 antibody | |
| SI1742644T1 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| MX361467B (en) | Isoindoline compounds for use in the treatment of cancer. | |
| WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
| TW200515910A (en) | Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer | |
| MX2010009670A (en) | Polymer paclitaxel conjugates and methods for treating cancer. | |
| WO2007050784A3 (en) | Fixed ratio drug combination treatments for solid tumors | |
| NO20083287L (en) | Drugs for the treatment of tumors, and their use | |
| MXPA03001227A (en) | 2-pyridinamine compositions and related methods. | |
| WO2005112999A3 (en) | Cancer treatment with inhibitors of collagen synthesis | |
| TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
| WO2005089294A3 (en) | Synthesis of indenoisoquinoliniums and methods of use | |
| WO2007110704A3 (en) | Macrolide compositions as therapeutic agent | |
| IL164356A (en) | Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer | |
| PT1618116E (en) | Ruthenium(ii) complexes for the treatment of tumors | |
| AU2003293665A1 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy | |
| WO2005023199A3 (en) | Socs-3 promoter methylation in cancer | |
| UA90658C2 (en) | Composition of a vegf antagonist and an anti-proliferative agent | |
| HK1123212A (en) | Fixed ratio drug combination treatments for solid tumors | |
| WO2004022001A3 (en) | Compositions and methods for inhibiting proliferation in human prostate cancer cells | |
| IL180460A (en) | COMBINED PREPARATION FOR TREATING CANCER COMPRISING AN ANTI-Hsp90 ANTIBODY AND AT LEAST ONE ANTI-CANCER AGENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |